Kymera Investor Presentation Deck

Relative Quantification (% Vehicle, p53/ACTB) 2000 1500- 1000 500 KT-253 Potently Degrades MDM2 and Upregulates the p53 Pathway in Preclinical Leukemia Models %MDM2 Remaining (Normalized to Vehicle, ACTB) 250 KYMERA 200 150 100 50 0 MDM2 Protein Levels (1h post dosing) 19% 6% 8% I p53 Protein Levels 1 824 1 824 1 824 1 824 1 824 1 824 Time (Hours) .*.** 10000 8000 6000 4000 2000 0 ©2023 KYMERA THERAPEUTICS, INC. Vehicle KT-253 3 mg/kg SD KT-253 1 mg/kg SD KT-253 0.3 mg/kg QWx3 DS-3032 30 mg/kg QDx3 DS-3032 100 mg/kg QDx3 GDF15 Protein Levels p53 Activation 1 824 1 8 24 1 8 24 1 824 1 8 24 1 8 24 Time (Hours) 2000 1500 1000 500 0 Targeted proteomic analysis of RS4;11 tumors demonstrates robust degradation of MDM2 one hour post dosing. This is associated with activation of the p53 pathway as evidenced by a corresponding upregulation of proteomics biomarkers p53, GDF15, p21 (cell cycle arrest marker) and PHLDA3 (apoptotic marker) p21 Protein Levels 1 8 24 1 8 24 1 824. 1 8 24 1 824 1824 Time (Hours) 2000 1500- 1000 500 1 824 PHLDA3 Protein Levels 1 8 24 1824 1 824 Time (Hours) 1 8 24 1 8 24 PAGE 55

View entire presentation